系统性硬化症患者缺血性与非缺血性心力衰竭风险:一项基于人群的研究
在瑞典全国登记中纳入1598例系统性硬化症(SSc)患者与16616名年龄性别匹配的对照,随访期间101例(6%)SSc患者发生心力衰竭(HF),对照组378例(2%)。SSc诊断后第一年末总体HF的HR为5.7(95%CI 4.2-7.9),缺血性HF为6.7(95%CI 3.5-13.0),非缺血性HF为5.8(95%CI 4.0-8.3)。
要点
- SSc患者HF发生率为6%(101/1598),对照为2%(378/16616)。
- SSc诊断后第一年末总体HF的HR为5.7(95%CI 4.2-7.9)。
- 缺血性HF的HR为6.7(95%CI 3.5-13.0),非缺血性HF的HR为5.8(95%CI 4.0-8.3)。
核心结论
- SSc与缺血性和非缺血性HF均相关,强调缺血以外机制如心肌细胞功能障碍、心肌纤维化和微血管损伤在SSc相关HF发生中的作用。
主要发现
- 研究队列共1598例SSc患者和16616名对照,随访期间101例(6%)SSc患者发生HF,对照378例(2%)发生HF。
- 两组中缺血性HF均占全部HF的35%,非缺血性HF均占65%。
- SSc诊断后第一年末总体HF的HR为5.7(95%CI 4.2-7.9),缺血性HF的HR为6.7(95%CI 3.5-13.0),非缺血性HF的HR为5.8(95%CI 4.0-8.3)。
- 总体HF、缺血性HF和非缺血性HF的相对风险均在SSc诊断后不久最高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the risk of incident ischaemic and non-ischaemic heart failure (HF) in a population-based cohort of all patients with SSc in Sweden compared with the general population. METHODS: We identified patients with incident SSc 2004-19 using nationwide Swedish registers and age- and sex-matched comparators from the general population (1:10). We started follow-up from the date of SSc diagnosis, the same date was assigned to the respective comparators. Our primary outcome was incident HF [International Statistical Classification of Diseases and Related Health Problems (ICD)-10: I50] as main diagnosis stratified into ischaemic and non-ischaemic HF depending on whether a visit listing ischaemic heart disease (ICD-10: I20-I25) was recorded before HF diagnosis or not. We used flexible parametric models to estimate hazard ratios (HRs) over time since SSc diagnosis. RESULTS: The study cohort comprised 1598 patients with SSc and 16 616 comparators. During follow-up, 101 (6%) patients with SSc developed HF compared with 378 (2%) of the comparators. Ischaemic HF represented 35% and non-ischaemic HF represented 65% of all HF cases in both groups. The relative risk of HF overall, ischaemic HF and non-ischaemic HF was highest soon after SSc diagnosis. HR at the end of the first year of follow-up was 5.7 (95% CI 4.2-7.9) for HF overall, 6.7 (95% CI 3.5-13.0) for ischaemic HF and 5.8 (95% CI 4.0-8.3) for non-ischaemic HF. CONCLUSION: SSc is associated with both ischaemic and non-ischaemic HF, emphasizing the role of other mechanisms than ischaemia, such as myocyte dysfunction, myocardial fibrosis and microvascular impairment, in the development of HF in SSc.
引用
- Bairkdar M, Faxén J, Arkema EV, et al. Risk of ischaemic and non-ischaemic heart failure in patients with systemic sclerosis: a population-based study. Rheumatology (Oxford). 2025. PMID: 40794713. doi:10.1093/rheumatology/keaf422
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。